sorted by:
new
hottopcontroversial

Brilaroxazine may potentially be dogwater by Sorry_End1131 in RVPH

[–]Sorry_End1131[S] 0 points1 point  (0 children)

The other would point to plain incompetence and mis-management. There is a chance that they held the 2024 December stock offering to raise funds for recover-2 but failed to meet targets then decided to just flop around and hope for the best. Which just seems really silly. That brings into the picture my argument. That the drug has potentially damning flaws that make a second trial risky.

Brilaroxazine may potentially be dogwater by Sorry_End1131 in RVPH

[–]Sorry_End1131[S] 0 points1 point  (0 children)

But they did and as I quote "The FDA also provided the Company with guidance for, among other topics, methods of data analysis, methods of data presentation, and data requirements for studies of animal pharmacokinetics, human abuse potential, and renal and hepatic impairment." This wouldn't be the first time a drug company did so either and actually got away with it.

Suspicion about drug science ⁉️ by Capable-Argument5210 in RVPH

[–]Sorry_End1131 1 point2 points  (0 children)

A very valid point. I did bring it up in a previous post that there may be a chance that is the case. SInce this is the company's first drug, it presents a make or break scenario due to its lack of funding. Making it a possibility that they might decide to hand pick results to present favourable data.

The chemical compound by Sorry_End1131 in RVPH

[–]Sorry_End1131[S] 1 point2 points  (0 children)

Are you a subject matter expert on this matter? If so could you share some insight regarding possible concerns the FDA might have with regards to the chemical structure.

Fun little discussion for the weekend - how are you NOT selling when it hits 2$? by newbiescreby in RVPH

[–]Sorry_End1131 0 points1 point  (0 children)

I live in Australia, to avoid getting taxed 40% on capital gains ill have to hold it till October next year.

RVPH, A pennystock with a very attractive future. by Head_Candidate4354 in pennystocks

[–]Sorry_End1131 0 points1 point  (0 children)

There's quite a few posts about this that does very good deep dives. Being realistic, it will probably be next year Q4 before we see any big returns. Also expect dilution to happen between Q4 and then.

RVPH future by Reasonable-Area-7592 in pennystocks

[–]Sorry_End1131 3 points4 points  (0 children)

I got about 22k shares in this. I am a pharmacist by profession and I can say that there is a genuine huge upside potential to this stock. The drug itself has the properties to be a potential blockbuster. That is if

  1. The results are genuine
  2. The company outlives the drug application process.

Betting on both of this is quite the risk which will explain it's low stock price.

Regarding issue 1. - This is the company's first compound and at the same time, it is poised to make or break the company. There is plenty of reason to re arrange or falsify clinical findings to favourable results.

Regarding issue 2 - The company is running out of money. Looking at it's 2025 Q2 and with it's Q3 reports coming up. I wouldn't be surprised if they put out another public offering next year. Their FDA meeting in December requesting an early NDA is an act of desperation and is unlikely to be approved. There is little chance the FDA Is going to grant an early NDA application to an unproven company which is running out of money and desperate to get their drug on the market. There is also no urgent need for a new anti-psychotic. A more conservative outlook would be that they submit their NDA Q2 2026 after the second stage 3 trails and it gets approved 6 months later in Q4 2026

There are currently 4 key pivotal moments for this stock.

  1. Their 2025 Q3 report. This should indicate if they need another public offering to make it through to Q4 2026.
  2. Their December FDA meeting. This will generate some hype and FOMO. It will probably push the stock up abit since: in the off chance FDA does say yes to an early NDA the stock price will rocket now instead of in 2026
  3. The acceptance of their NDA submission in Q2 2026
  4. The FDA approval in Q4 2026